May Mabro

3.1k total citations
54 papers, 1.5k citations indexed

About

May Mabro is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, May Mabro has authored 54 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 13 papers in Hepatology. Recurrent topics in May Mabro's work include Colorectal Cancer Treatments and Studies (35 papers), Cancer Treatment and Pharmacology (22 papers) and Gastric Cancer Management and Outcomes (16 papers). May Mabro is often cited by papers focused on Colorectal Cancer Treatments and Studies (35 papers), Cancer Treatment and Pharmacology (22 papers) and Gastric Cancer Management and Outcomes (16 papers). May Mabro collaborates with scholars based in France, Austria and Canada. May Mabro's co-authors include Thierry André, Aimery de Gramont, Christophe Louvet, Élisabeth Carola, Pascal Artru, F. Maindrault-Gœbel, Christophe Tournigand, M Krulik, Gérard Lledo and Laurent Mineur and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

May Mabro

53 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
May Mabro France 19 1.3k 520 403 288 254 54 1.5k
H. Kröning Germany 13 1.0k 0.8× 592 1.1× 231 0.6× 254 0.9× 199 0.8× 26 1.5k
Joseph J. Schulz United States 6 1.3k 1.0× 533 1.0× 469 1.2× 195 0.7× 148 0.6× 8 1.5k
José María Viéitez Spain 14 1.1k 0.9× 563 1.1× 290 0.7× 132 0.5× 195 0.8× 52 1.4k
Janja Ocvirk Slovenia 17 1.0k 0.8× 376 0.7× 226 0.6× 231 0.8× 179 0.7× 69 1.3k
Karen Rittweger United States 14 967 0.8× 367 0.7× 173 0.4× 280 1.0× 248 1.0× 17 1.3k
Élisabeth Carola France 17 2.2k 1.8× 852 1.6× 680 1.7× 415 1.4× 338 1.3× 58 2.5k
Clemens Gießen Germany 20 944 0.8× 548 1.1× 288 0.7× 252 0.9× 271 1.1× 46 1.1k
İrfan Çiçin Türkiye 21 1.2k 1.0× 901 1.7× 150 0.4× 338 1.2× 159 0.6× 141 1.9k
Paolo Alessandroni Italy 17 778 0.6× 457 0.9× 255 0.6× 386 1.3× 150 0.6× 37 1.2k
Mitsukuni Suenaga Japan 21 1.1k 0.9× 533 1.0× 147 0.4× 240 0.8× 205 0.8× 149 1.5k

Countries citing papers authored by May Mabro

Since Specialization
Citations

This map shows the geographic impact of May Mabro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by May Mabro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites May Mabro more than expected).

Fields of papers citing papers by May Mabro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by May Mabro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by May Mabro. The network helps show where May Mabro may publish in the future.

Co-authorship network of co-authors of May Mabro

This figure shows the co-authorship network connecting the top 25 collaborators of May Mabro. A scholar is included among the top collaborators of May Mabro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with May Mabro. May Mabro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Randrian, Violaine, Fabienne Portales, Olivier Bouché, et al.. (2025). The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors. Journal of Neuro-Oncology. 172(1). 229–238.
2.
Neuzillet, Cindy, Olivier Bouché, Christophe Tournigand, et al.. (2023). Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial. Journal of the National Comprehensive Cancer Network. 21(12). 1234–1242.e17. 13 indexed citations
3.
4.
5.
Taı̈eb, Julien, Valérie Taly, Julie Henriques, et al.. (2021). Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. Clinical Cancer Research. 27(20). 5638–5646. 71 indexed citations
6.
Taı̈eb, Julien, Franck Bonnetain, Laurent Mineur, et al.. (2017). Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results. Annals of Oncology. 28. v158–v158. 9 indexed citations
7.
Hebbar, Mohamed, Benoist Chibaudel, Thierry André, et al.. (2013). Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study. Journal of Chemotherapy. 25(2). 104–111. 6 indexed citations
8.
9.
Chibaudel, Benoist, Frédérique Maindrault‐Gœbel, Gérard Lledo, et al.. (2009). Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. Journal of Clinical Oncology. 27(34). 5727–5733. 262 indexed citations
10.
Bidard, François‐Clément, Christophe Tournigand, Thierry André, et al.. (2009). Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Annals of Oncology. 20(6). 1042–1047. 32 indexed citations
11.
André, Thierry, Christophe Tournigand, Laurent Mineur, et al.. (2006). Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Annals of Oncology. 18(1). 77–81. 38 indexed citations
12.
Hebbar, Mohamed, Christophe Tournigand, Gérard Lledo, et al.. (2006). Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study). Cancer Investigation. 24(2). 154–159. 24 indexed citations
13.
Mabro, May, Pascal Artru, Thierry André, et al.. (2006). A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. British Journal of Cancer. 94(9). 1287–1292. 35 indexed citations
14.
Maindrault-Gœbel, F., Christophe Tournigand, Thierry André, et al.. (2004). Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Annals of Oncology. 15(8). 1210–1214. 70 indexed citations
15.
Louvet, Christophe, Fabrice Carrat, Frédéric Mal, et al.. (2003). Prognostic Factor Analysis in Advanced Gastric Cancer Patients Treated with Hydroxyurea, Leucovorin, 5-Fluorouracil, and Cisplatin (HLFP Regimen). Cancer Investigation. 21(1). 14–20. 19 indexed citations
16.
Gramont, Aimery de, Christophe Louvet, Thierry André, et al.. (2000). Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Annals of Oncology. 11(11). 1477–1483. 101 indexed citations
17.
Mabro, May, Christophe Louvet, Élisabeth Carola, et al.. (1999). 5-fluorouracile bimensuel en traitement du cancer colorectal métastasé chez le sujet âgé. Étude de 50 patients. La Revue de Médecine Interne. 20(10). 863–868. 10 indexed citations
18.
Mabro, May, Sandrine Faivre, & Éric Raymond. (1999). A Risk-Benefit Assessment of Amifostine in Cytoprotection. Drug Safety. 21(5). 367–387. 30 indexed citations
19.
André, Thierry, Christophe Louvet, F. Maindrault-Gœbel, et al.. (1999). CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. European Journal of Cancer. 35(9). 1343–1347. 222 indexed citations
20.
Mabro, May, et al.. (1999). [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].. PubMed. 86(3). 295–301. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Kröning Breakdown of academic impact, for papers by Joseph J. Schulz Breakdown of academic impact, for papers by José María Viéitez Breakdown of academic impact, for papers by Janja Ocvirk Breakdown of academic impact, for papers by Karen Rittweger Breakdown of academic impact, for papers by Élisabeth Carola Breakdown of academic impact, for papers by Clemens Gießen Breakdown of academic impact, for papers by İrfan Çiçin Breakdown of academic impact, for papers by Paolo Alessandroni Breakdown of academic impact, for papers by Mitsukuni Suenaga
Rankless by CCL
2026